Related Experiment Video
Updated: Apr 28, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development
Henry Enzama1, Francis Williams Ojara1,2, Ian S Haworth3
1Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
None:
Across low- and middle-income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model-informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake. Physiologically based and population pharmacokinetic modeling can strengthen regulatory review and optimize dosing. When aligned with global harmonization initiatives, these tools can support evidence-based decisions and advance pharmacoequity by ensuring context-appropriate therapies reach patients.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Overview
Analysis of Population Pharmacokinetic Data
Pharmacokinetic–Pharmacodynamic Relationship: Problems

